Search Results
Jun 16, 2026, 08:00 ET ProJenX Announces a Development Update for Prosetin, a First-in-Class, CNS-Penetrant MAP4K Inhibitor
other debilitating brain diseases, today announced a clinical update from PRO-101, a Phase 1b clinical study evaluating prosetin—a potent, selective, CNS-penetrant MAP4K inhibitor—in participants with ALS. PRO-101 was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and target engagement
More news about: ProJenX
Jun 16, 2026, 08:00 ET Verge Labs Unveils vBx: A Breakthrough Foundation Model for Precision Neurology
collaborations to validate its performance on partners' clinical trial datasets. Earlier this month the company announced its first platform partnership, a CNS collaboration with Tenacia Biotechnology. "If you have a trial that failed in a mixed population, or you're designing one now, we want to run the virtual
More news about: Verge Labs
Jun 15, 2026, 12:31 ET EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
Pharmaceuticals' Firmonertinib, previously referred to as furmonertinib, is an orally administered, mutation-selective EGFR inhibitor recognized for its strong CNS penetration and activity against a broad spectrum of EGFR mutations, including uncommon variants such as PACC and Exon 20 insertion mutations. The therapy
More news about: DelveInsight Business Research, LLP
Jun 15, 2026, 10:25 ET SK Life Science, Inc. Announces FDA Acceptance for Review of New Drug Application for Cenobamate Oral Suspension
pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with 12 compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high content
More news about: SK Life Science, Inc.
Jun 15, 2026, 09:50 ET Cohen & Steers Completes Conversion of Future of Energy Mutual Fund to Active ETF
NEW YORK, June 15, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced it has completed the conversion the Cohen & Steers Future of Energy Fund (MLOIX) into a new, actively managed exchanged-traded fund
More news about: Cohen & Steers, Inc.
Jun 15, 2026, 09:00 ET NEURELIS CEO CRAIG CHAMBLISS NAMED EY US ENTREPRENEUR OF THE YEAR® 2026 PACIFIC SOUTHWEST AWARD WINNER
Hypersensitivity to diazepamAcute narrow-angle glaucomaCentral Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Jun 12, 2026, 10:00 ET Transcend Therapeutics Announces Completion of Acquisition by Otsuka Pharmaceutical
receptors (i.e., not hallucinogenic). Transcend is developing TSND-201 as a rapid-acting and durable treatment for PTSD and other central nervous system (CNS) indications. TSND-201 is an investigational medication.About Transcend TherapeuticsTranscend, founded in 2021 and based in New
More news about: Transcend Therapeutics
Jun 12, 2026, 09:00 ET Braeburn to Present Research at CPDD 2026 Annual Meeting, Including Data on Withdrawal Suppression and Real-World Treatment Retention in Patients With Opioid Use Disorder
emergency medical help, even if an agent is administered.Concomitant Use of Benzodiazepines or other CNS Depressants: Concomitant use of buprenorphine and benzodiazepines or other CNS depressants (e.g., alcohol, non-benzodiazepine sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants,
More news about: Braeburn
Jun 12, 2026, 08:00 ET Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
pivotal trial that supported the second-line accelerated approval, including patients with a history of CNS involvement. Efficacy of Zepzelca in the subset of patients without a history of CNS involvement was more comparable to the control arm, which performed better than historical precedent.
More news about: Jazz Pharmaceuticals plc
Jun 11, 2026, 11:34 ET Cognision Publishes Landmark Study Showing Ketamine Produces Opposite Brain Effects in Different Patients -- and That Outcome Can Be Predicted Using EEG
Biomarker Qualification Consortium — a collaborative body that includes Cognision and ten pharmaceutical companies focused on central nervous system (CNS) disorders — to investigate the electrophysiological changes these compounds induce in the brain.The Consortium previously published research
More news about: Cognision
Jun 11, 2026, 10:01 ET Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsight
advanced Phase II/III neuroactive therapy candidate under investigation both as a standalone treatment and in combination with EXV-801 to address multiple CNS signaling pathways associated with agitation. This reflects an industry-wide move toward multi-target and combination-based therapeutic strategies intended
More news about: DelveInsight Business Research, LLP
Jun 11, 2026, 08:01 ET New York Proton Center Presents Advances in Proton Therapy Across Multiple Cancers at PTCOG 64
proton therapy center present data demonstrating the benefits of proton therapy in spinal, uterine, cervical, thoracic, gastrointestinal, breast, CNS, and head and neck cancers, and game-changing innovations, including ultra-high dose rate FLASH therapy NYPC has the most
More news about: New York Proton Center
Jun 11, 2026, 03:00 ET Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
in 1947 and headquartered in Seoul, South Korea, is a pharmaceutical company with core expertise in ophthalmology, hepatology, gastroenterology, and CNS disorders. As part of its global expansion strategy, Samil operates overseas subsidiaries in North America, Vietnam, and Japan. Through ongoing partnerships
More news about: Formosa Pharmaceuticals Inc.,
Jun 10, 2026, 10:01 ET Developmental and Epileptic Encephalopathies Market to Register Immense Growth at a CAGR of 11.7% During the Forecast Period (2026-2036) Due to the Launch of Next-Generation Gene and Targeted Therapies | DelveInsight
drug profiles, including clinical and non-clinical stage products, and the key DEE companies, including Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen,
More news about: DelveInsight Business Research, LLP
Jun 09, 2026, 11:00 ET Academy of Emergency Nursing to Induct Eight Fellows
the Academy recognizes: enduring and substantial contributions to the specialty of emergency nursing," said AEN Board Chairperson Andi Foley, DNP, APRN-CNS, EMT, CEN, FAEN. "Their leadership has led to advancements across the profession in the areas of research, education, clinical practice and advocacy.
More news about: Emergency Nurses Association
Jun 09, 2026, 10:05 ET Verge Labs and Tenacia Biotechnology Partner to Advance Tenacia's CNS Pipeline Using Human Data
in May. It is the first of several CNS engagements now underway, reflecting the growing demand for answers drawn directly from human data at the points in development where programs often fail.Verge Labs is built on one of the largest proprietary multimodal CNS patient datasets of its kind: more
More news about: Verge Labs
Jun 09, 2026, 09:39 ET Lynk Pharmaceuticals' Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor
readout expected in early 2027.BLKR201 / LNK01006 is a novel, selective CNS-penetrant allosteric TYK2 inhibitor designed to regulate immune signaling within the central nervous system. TYK2 is a validated target, and the CNS exposure and high target selectivity of this compound may open up opportunities
More news about: Lynk Pharmaceuticals Co., Ltd.
Jun 09, 2026, 09:00 ET Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
them."BLKR201 is an investigational next-generation, CNS-penetrant allosteric TYK2 inhibitor designed to regulate immune signaling within the central nervous system. While TYK2 is a validated target with an established clinical safety profile, the CNS exposure and high target selectivity of BLKR201 may
More news about: Formation Bio
Jun 09, 2026, 08:00 ET LG CNS Hosts "Optimization Grand Challenge 2026" to Tackle Real-World Industrial Challenges Using Mathematics
Senior Vice President of LG CNS' Entrue Unit. "By raising both the prize pool and the level of challenge this year, we hope to further expand the reach of optimization technologies together with outstanding talent from around the world."About LG CNSLG CNS is a leading Korean software
More news about: LG CNS
Jun 09, 2026, 05:13 ET Whole-Body Spatial Intelligence Beyond Weight-loss: nference Advances Cardiometabolism Moat for Precision Peptide Medicines and Healthy Longevity
semaglutide-associated incident risk reduction includes substance disorders, mood-, anxiety- and stress-related conditions, central nervous system (CNS) atrophy, neuromuscular diseases, sleep disturbances, behavioral disorders, and impulse control diseases. By extending beyond one or two neuropsychiatric
More news about: nference
Jun 08, 2026, 16:20 ET Cohen & Steers Quality Income Realty Fund, Inc. Declares Distributions for July, August, and September 2026
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers Quality Income Realty Fund, Inc.
Jun 08, 2026, 16:15 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2026
NEW YORK, June 8, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $99.5 billion as of May 31, 2026, a decrease of $645 million from assets under management of $100.1
More news about: Cohen & Steers, Inc.
Jun 08, 2026, 09:15 ET Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
guiding more precise surgical interventions and personalized treatment choices."Until now, we were unable to study large tissue sections in CNS and other cancer types at a whole-transcriptome, single-cell level," said Ania Piskorz, PhD, the Head of Genomics at the Cancer Research UK Cambridge
More news about: Illumina, Inc.
Jun 08, 2026, 08:00 ET Going Beyond Vibe Coding: Agentic AI Takes on Large-scale System Development
like code analysis, conversion, and validation, which previously required weeks of effort. With LG CNS' platform, all these tasks can be completed in minutes, dramatically improving productivity. LG CNS is already deploying its COBOL-to-Java conversion capability, powered by Cline Spec Driven for Enterprise,
More news about: LG CNS
Jun 08, 2026, 05:00 ET Foresee's Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2a Platform Trial
data. We are confident the results from this study will provide a strong foundation for further development in PD and other CNS diseases as this study will provide data related to CNS penetration and target/biomarker engagement of mirivadelgat".About mirivadelgatResearch suggests
More news about: Foresee Pharmaceuticals Co., Ltd.